{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:04:19Z","timestamp":1768813459614,"version":"3.49.0"},"reference-count":231,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.lfs.2020.118123","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T11:22:32Z","timestamp":1595416952000},"page":"118123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["New vistas in malignant mesothelioma: MicroRNA architecture and NRF2\/MAPK signal transduction"],"prefix":"10.1016","volume":"257","author":[{"given":"Manav","family":"Gandhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujit","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2020.118123_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061603","article-title":"Heterogeneity in malignant pleural mesothelioma","volume":"19","author":"Oehl","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2020.118123_bb0010","author":"Global Cancer Observatory"},{"key":"10.1016\/j.lfs.2020.118123_bb0015","author":"Global Cancer Observatory"},{"key":"10.1016\/j.lfs.2020.118123_bb0020","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/0019-5278.146897","article-title":"Global mesothelioma epidemic: trend and features","volume":"18","author":"Bianchi","year":"2014","journal-title":"Indian J Occup Environ Med"},{"key":"10.1016\/j.lfs.2020.118123_bb0025","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1586\/17476348.2015.1081066","article-title":"Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies","volume":"9","author":"Bononi","year":"2015","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.lfs.2020.118123_bb0030","author":"National Cancer Institue"},{"key":"10.1016\/j.lfs.2020.118123_bb0035","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3389\/fonc.2019.01519","article-title":"Malignant pleural mesothelioma: state-of-the-art on current therapies and promises for the future","volume":"9","author":"Nicolini","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2020.118123_bb0040","author":"Kazan-Allen"},{"key":"10.1016\/j.lfs.2020.118123_bb0045","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev.iy.12.040194.002005","article-title":"Tumor antigens recognized by T lymphocytes","volume":"12","author":"Boon","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.lfs.2020.118123_bb0050","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.biopha.2017.07.075","article-title":"Regulation of microRNA using promising dietary phytochemicals: possible preventive and treatment option of malignant mesothelioma","volume":"94","author":"Sayeed","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2020.118123_bb0055","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-3-642-10862-4_5","article-title":"Pathohistological diagnosis and differential diagnosis","volume":"189","author":"Tischoff","year":"2011","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.lfs.2020.118123_bb0060","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12199-007-0017-6","article-title":"Pathology of mesothelioma","volume":"13","author":"Inai","year":"2008","journal-title":"Environ. Health Prev. Med."},{"key":"10.1016\/j.lfs.2020.118123_bb0065","doi-asserted-by":"crossref","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group","volume":"137","author":"Husain","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.lfs.2020.118123_bb0070","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1440-1827.2010.02560.x","article-title":"Lymphohistiocytoid mesothelioma of the pleura","volume":"60","author":"Kawai","year":"2010","journal-title":"Pathol. Int."},{"key":"10.1016\/j.lfs.2020.118123_bb0075","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.5858\/2010-0086-RAR.1","article-title":"Sarcomatoid neoplasms of the lung and pleura","volume":"134","author":"Travis","year":"2010","journal-title":"Arch Pathol Lab Med."},{"key":"10.1016\/j.lfs.2020.118123_bb0080","first-page":"E254","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"van Zandwijk","year":"2013","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.lfs.2020.118123_bb0085","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11864-008-0067-z","article-title":"Mesothelioma epidemiology, carcinogenesis, and pathogenesis","volume":"9","author":"Yang","year":"2008","journal-title":"Curr. Treat. Options in Oncol."},{"key":"10.1016\/j.lfs.2020.118123_bb0090","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(00)04013-7","article-title":"Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey","volume":"357","author":"Roushdy-Hammady","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.118123_bb0095","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1158\/0008-5472.CAN-05-4642","article-title":"Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey","volume":"66","author":"Dogan","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2020.118123_bb0100","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-14-1328","article-title":"Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2020.118123_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrrev.2019.03.001","article-title":"Genetic predisposition for malignant mesothelioma: a concise review","volume":"781","author":"Betti","year":"2019","journal-title":"Mutat. Res."},{"key":"10.1016\/j.lfs.2020.118123_bb0110","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ncponc1039","article-title":"Advances in the systemic therapy of malignant pleural mesothelioma","volume":"5","author":"Fennell","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.lfs.2020.118123_bb0115","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/JTO.0b013e3182208e3f","volume":"6","author":"Rice","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2020.118123_bb0120","doi-asserted-by":"crossref","first-page":"272S","DOI":"10.1378\/chest.112.4_Supplement.272S","article-title":"Multimodality therapy for malignant pleural mesothelioma","volume":"112","author":"Sugarbaker","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.lfs.2020.118123_bb0125","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.chest.2016.12.004","article-title":"Malignant mesothelioma biomarkers: from discovery to use in clinical practice for diagnosis, monitoring, screening, and treatment","volume":"152","author":"Creaney","year":"2017","journal-title":"Chest."},{"key":"10.1016\/j.lfs.2020.118123_bb0130","doi-asserted-by":"crossref","first-page":"S1003","DOI":"10.21037\/jtd.2018.04.31","article-title":"Biomarkers in malignant pleural mesothelioma: current status and future directions","volume":"10","author":"Ahmadzada","year":"2018","journal-title":"J Thorac Dis."},{"key":"10.1016\/j.lfs.2020.118123_bb0135","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.lungcan.2013.09.016","article-title":"Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma","volume":"82","author":"Creaney","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lfs.2020.118123_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072030","article-title":"Hyaluronan and N-ERC\/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma","volume":"8","author":"Mundt","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.118123_bb0145","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2174\/156800912801784875","article-title":"Emerging roles for modulation of microRNA signatures in cancer chemoprevention","volume":"12","author":"Neelakandan","year":"2012","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.lfs.2020.118123_bb0150","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3934\/molsci.2016.2.104","article-title":"Current insights into the molecular systems pharmacology of lncRNA-miRNA regulatory interactions and implications in cancer translational medicine","volume":"3","author":"Nair","year":"2016","journal-title":"AIMS Molecular Science"},{"key":"10.1016\/j.lfs.2020.118123_bb0155","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40495-014-0014-6","article-title":"Architecture of signature miRNA regulatory networks in cancer chemoprevention","volume":"1","author":"Nair","year":"2015","journal-title":"Current Pharmacology Reports"},{"key":"10.1016\/j.lfs.2020.118123_bb0160","first-page":"61","article-title":"New perspectives in personalised medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics","volume":"33","author":"Nair","year":"2018"},{"key":"10.1016\/j.lfs.2020.118123_bb0165","article-title":"miR-625-3p and lncRNA GAS5 in liquid biopsies for predicting the outcome of malignant pleural mesothelioma patients treated with neo-adjuvant chemotherapy and surgery","volume":"5","author":"Kresoja-Rakic","year":"2019","journal-title":"Noncoding RNA"},{"key":"10.1016\/j.lfs.2020.118123_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48133-0","article-title":"Exosomal miR-16-5p as a target for malignant mesothelioma","volume":"9","author":"Munson","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2020.118123_bb0175","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1002\/1878-0261.12386","article-title":"Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma","volume":"12","author":"He","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.lfs.2020.118123_bb0180","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8628612","article-title":"MicroRNA signatures in malignant pleural mesothelioma effusions","volume":"2019","author":"Birnie","year":"2019","journal-title":"Dis. Markers"},{"key":"10.1016\/j.lfs.2020.118123_bb0185","article-title":"In silico transcriptomic analysis of wound-healing-associated genes in malignant pleural mesothelioma","volume":"55","author":"Rouka","year":"2019","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.lfs.2020.118123_bb0190","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2217\/bmm-2017-0224","article-title":"Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients","volume":"12","author":"Matboli","year":"2018","journal-title":"Biomark. Med"},{"key":"10.1016\/j.lfs.2020.118123_bb0195","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1002\/jcb.27586","article-title":"Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa-miR-2053 and lncRNA-RP1-86D1.3 axis expression in malignant pleural mesothelioma","volume":"120","author":"Matboli","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.lfs.2020.118123_bb0200","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.7150\/ijbs.13453","article-title":"Blockage of epithelial to mesenchymal transition and upregulation of let 7b are critically involved in ursolic acid induced apoptosis in malignant mesothelioma cell","volume":"12","author":"Sohn","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.lfs.2020.118123_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2020.105700","article-title":"Mechanism of miR-222 and miR-126 regulation and its role in asbestos-induced malignancy","volume":"121","author":"Gaetani","year":"2020","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.lfs.2020.118123_bb0210","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/15384047.2017.1415677","article-title":"Micro-RNA149 confers taxane resistance to malignant mesothelioma cells via regulation of P-glycoprotein expression","volume":"19","author":"Kenworthy","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.lfs.2020.118123_bb0215","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"key":"10.1016\/j.lfs.2020.118123_bb0220","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1186\/s12859-019-3105-x","article-title":"MIENTURNET: an interactive web tool for microRNA-target enrichment and network-based analysis","volume":"20","author":"Licursi","year":"2019","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.lfs.2020.118123_bb0225","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.05005","article-title":"Predicting effective microRNA target sites in mammalian mRNAs","volume":"4","author":"Agarwal","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.lfs.2020.118123_bb0230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: Kyoto encyclopedia of genes and genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.lfs.2020.118123_bb0235","doi-asserted-by":"crossref","first-page":"D590","DOI":"10.1093\/nar\/gky962","article-title":"New approach for understanding genome variations in KEGG","volume":"47","author":"Kanehisa","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.lfs.2020.118123_bb0240","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/pro.3715","article-title":"Toward understanding the origin and evolution of cellular organisms","volume":"28","author":"Kanehisa","year":"2019","journal-title":"Protein Sci."},{"key":"10.1016\/j.lfs.2020.118123_bb0245","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/1055-9965.EPI-18-0453","article-title":"Four-miRNA signature to identify asbestos-related lung malignancies","volume":"28","author":"Santarelli","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.lfs.2020.118123_bb0250","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0255","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.18632\/oncotarget.27010","article-title":"Transcriptional suppression of the miR-15\/16 family by c-Myc in malignant pleural mesothelioma","volume":"10","author":"Williams","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2020.118123_bb0260","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jtho.2017.10.016","article-title":"Dysregulated expression of the microRNA miR-137 and its target YBX1 contribute to the invasive characteristics of malignant pleural mesothelioma","volume":"13","author":"Johnson","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2020.118123_bb0265","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-016-0387-6","article-title":"Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism","volume":"10","author":"El Bezawy","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lfs.2020.118123_bb0270","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.ymthe.2019.05.020","article-title":"MicroRNA-215-5p treatment suppresses mesothelioma progression via the MDM2-p53-signaling axis","volume":"27","author":"Singh","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lfs.2020.118123_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176680","article-title":"Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease","volume":"12","author":"Cavalleri","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.118123_bb0280","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/1878-0261.12150","article-title":"A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma","volume":"12","author":"Schelch","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.lfs.2020.118123_bb0285","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/1541-7786.MCR-14-0442","article-title":"Loss of miR-223 and JNK signaling contribute to elevated stathmin in malignant pleural mesothelioma","volume":"13","author":"Birnie","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.lfs.2020.118123_bb0290","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1080\/17435390.2018.1465139","article-title":"Inflammation in the pleural cavity following injection of multi-walled carbon nanotubes is dependent on their characteristics and the presence of IL-1 genes","volume":"12","author":"Arnoldussen","year":"2018","journal-title":"Nanotoxicology"},{"key":"10.1016\/j.lfs.2020.118123_bb0295","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13104-019-4113-7","article-title":"Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case-control study","volume":"12","author":"Weber","year":"2019","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.lfs.2020.118123_bb0300","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0305","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lfs.2020.118123_bb0310","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.canlet.2019.08.001","article-title":"Exosomal transfer of miR-126 promotes the anti-tumour response in malignant mesothelioma: role of miR-126 in cancer-stroma communication","volume":"463","author":"Monaco","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.lfs.2020.118123_bb0315","doi-asserted-by":"crossref","DOI":"10.1158\/1940-6207.CAPR-19-0522","article-title":"Epigenome, transcriptome and protection by sulforaphane at different stages of UVB-induced skin carcinogenesis","author":"Li","year":"2020","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.lfs.2020.118123_bb0320","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/mc.23146","article-title":"Epigenetics\/epigenomics and prevention by curcumin of early stages of inflammatory-driven colon cancer","volume":"59","author":"Wu","year":"2020","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.lfs.2020.118123_bb0325","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.118123_bb0330","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1164\/rccm.200511-1789OC","article-title":"Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma","volume":"173","author":"Scherpereel","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lfs.2020.118123_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018232","article-title":"Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma","volume":"6","author":"Santarelli","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.118123_bb0340","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.4161\/epi.6.8.16074","article-title":"The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma","volume":"6","author":"Nelson","year":"2011","journal-title":"Epigenetics"},{"key":"10.1016\/j.lfs.2020.118123_bb0345","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.lungcan.2015.09.021","article-title":"Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma","volume":"90","author":"Santarelli","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lfs.2020.118123_bb0350","first-page":"6223","article-title":"Methylation-associated silencing of microRNA-126 and its host gene EGFL7 in malignant pleural mesothelioma","volume":"35","author":"Andersen","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lfs.2020.118123_bb0355","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1158\/1078-0432.CCR-10-3040","article-title":"Epigenetic silencing of microRNA-34b\/c plays an important role in the pathogenesis of malignant pleural mesothelioma","volume":"17","author":"Kubo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2020.118123_bb0360","first-page":"2139","article-title":"Droplet digital PCR as a novel system for the detection of microRNA34b\/c methylation in circulating DNA in malignant pleural mesothelioma","volume":"54","author":"Sato","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.lfs.2020.118123_bb0365","doi-asserted-by":"crossref","first-page":"5741","DOI":"10.1158\/0008-5472.CAN-18-0655","article-title":"A polysome-based microRNA screen identifies miR-24-3p as a novel promigratory miRNA in mesothelioma","volume":"78","author":"Oliveto","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2020.118123_bb0370","doi-asserted-by":"crossref","first-page":"22254","DOI":"10.18632\/oncotarget.24962","article-title":"Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy","volume":"9","author":"Mairinger","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2020.118123_bb0375","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20225817","article-title":"Molecular signatures for combined targeted treatments in diffuse malignant peritoneal mesothelioma","volume":"20","author":"Belfiore","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2020.118123_bb0380","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1745-7254.2007.00549.x","article-title":"Natural dietary anti-cancer chemopreventive compounds: redox-mediated differential signaling mechanisms in cytoprotection of normal cells versus cytotoxicity in tumor cells","volume":"28","author":"Nair","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.lfs.2020.118123_bb0385","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.fct.2016.08.033","article-title":"Cisplatin and resveratrol induce apoptosis and autophagy following oxidative stress in malignant mesothelioma cells","volume":"97","author":"Lee","year":"2016","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.lfs.2020.118123_bb0390","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3892\/or.2015.4382","article-title":"Auranofin induces mesothelioma cell death through oxidative stress and GSH depletion","volume":"35","author":"You","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.lfs.2020.118123_bb0395","article-title":"Induction of gamma-glutamyltransferase activity and consequent prooxidant reactions in human macrophages exposed to crocidolite asbestos","author":"Corti","year":"2019","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.lfs.2020.118123_bb0400","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.3892\/or.2015.3830","article-title":"Pemetrexed induces apoptosis in malignant mesothelioma and lung cancer cells through activation of reactive oxygen species and inhibition of sirtuin 1","volume":"33","author":"Hwang","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.lfs.2020.118123_bb0405","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1081\/DMR-120000652","article-title":"Induction of xenobiotic enzymes by the MAP kinase pathway and the antioxidant or electrophile response element (ARE\/EpRE)","volume":"33","author":"Kong","year":"2001","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.lfs.2020.118123_bb0410","doi-asserted-by":"crossref","first-page":"39907","DOI":"10.1074\/jbc.M004037200","article-title":"Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism","volume":"275","author":"Yu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2020.118123_bb0415","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.freeradbiomed.2017.12.005","article-title":"Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer","volume":"115","author":"Ciamporcero","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.lfs.2020.118123_bb0420","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/tox.22734","article-title":"Regorefenib induces extrinsic\/intrinsic apoptosis and inhibits MAPK\/NF-kappaB-modulated tumor progression in bladder cancer in vitro and in vivo","volume":"34","author":"Chiang","year":"2019","journal-title":"Environ. Toxicol."},{"key":"10.1016\/j.lfs.2020.118123_bb0425","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2647068","article-title":"NRF1 and NRF2 mRNA and protein expression decrease early during melanoma carcinogenesis: an insight into survival and microRNAs","volume":"2019","author":"Hamalainen","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.lfs.2020.118123_bb0430","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708446","article-title":"Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma","volume":"10","author":"Echevarria-Vargas","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.lfs.2020.118123_bb0435","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/mc.22745","article-title":"The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer","volume":"57","author":"Tao","year":"2018","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.lfs.2020.118123_bb0440","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/1535-7163.MCT-17-0464","article-title":"RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade","volume":"17","author":"Bockorny","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lfs.2020.118123_bb0445","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.18632\/oncotarget.3543","article-title":"NF2 blocks snail-mediated p53 suppression in mesothelioma","volume":"6","author":"Cho","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2020.118123_bb0450","first-page":"91","article-title":"DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma","volume":"51","author":"Wang","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.lfs.2020.118123_bb0455","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.freeradbiomed.2017.12.008","article-title":"Modulation of reactive oxygen species via ERK and STAT3 dependent signalling are involved in the response of mesothelioma cells to exemestane","volume":"115","author":"Nuvoli","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.lfs.2020.118123_bb0460","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.freeradbiomed.2017.02.011","article-title":"Rheostatic CD44 isoform expression and its association with oxidative stress in human malignant mesothelioma","volume":"106","author":"Chew","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.lfs.2020.118123_bb0465","doi-asserted-by":"crossref","first-page":"39861","DOI":"10.18632\/oncotarget.9515","article-title":"Inhibition of FGF\/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039\/GSK3052230","volume":"7","author":"Blackwell","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2020.118123_bb0470","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/1078-0432.CCR-17-1172","article-title":"Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition","volume":"24","author":"Quispel-Janssen","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2020.118123_bb0475","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.cellsig.2015.07.017","article-title":"Syndecan-1 alters heparan sulfate composition and signaling pathways in malignant mesothelioma","volume":"27","author":"Heidari-Hamedani","year":"2015","journal-title":"Cell. Signal."},{"key":"10.1016\/j.lfs.2020.118123_bb0480","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bcp.2015.08.103","article-title":"PKC-delta\/PKC-alpha activity balance regulates the lethal effects of cisplatin","volume":"98","author":"Muscella","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118123_bb0485","article-title":"Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo","volume":"8","author":"Li","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2020.118123_bb0490","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/jphp.13012","article-title":"Investigation of potent anticarcinogenic activity of 1, 3-diarylpyrazole acrylamide derivatives in vitro","volume":"70","author":"Demiroglu-Zergeroglu","year":"2018","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118123_bb0495","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jtho.2016.10.023","article-title":"Trametinib plus 4-methylumbelliferone exhibits antitumor effects by ERK blockade and CD44 downregulation and affects PD-1 and PD-L1 in malignant pleural mesothelioma","volume":"12","author":"Cho","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2020.118123_bb0500","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1091581815591223","article-title":"MWCNTs induce ROS generation, ERK phosphorylation, and SOD-2 expression in human mesothelial cells","volume":"35","author":"Yu","year":"2016","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.lfs.2020.118123_bb0505","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jtho.2015.09.004","article-title":"Functional analysis of the adrenomedullin pathway in malignant pleural mesothelioma","volume":"11","author":"Greillier","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2020.118123_bb0510","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1002\/jcp.26128","article-title":"Inhibition of ZL55 cell proliferation by ADP via PKC-dependent signalling pathway","volume":"233","author":"Muscella","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.lfs.2020.118123_bb0515","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jphs.2017.05.005","article-title":"Connexin 43 enhances Bax activation via JNK activation in sunitinib-induced apoptosis in mesothelioma cells","volume":"134","author":"Uzu","year":"2017","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.lfs.2020.118123_bb0520","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000489128","article-title":"A succinate ether derivative of tocotrienol enhances Dickkopf-1 gene expression through epigenetic alterations in malignant mesothelioma cells","volume":"102","author":"Sato","year":"2018","journal-title":"Pharmacology"},{"key":"10.1016\/j.lfs.2020.118123_bb0525","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/cas.13871","article-title":"Establishment and characterization of CRISPR\/Cas9-mediated NF2(\u2212\/\u2212) human mesothelial cell line: molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma","volume":"110","author":"Wahiduzzaman","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lfs.2020.118123_bb0530","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jphs.2015.10.003","article-title":"Diarachidonoylphosphoethanolamine induces apoptosis of malignant pleural mesothelioma cells through a Trx\/ASK1\/p38 MAPK pathway","volume":"129","author":"Tsuchiya","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.lfs.2020.118123_bb0535","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12885-015-1363-1","article-title":"The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma","volume":"15","author":"Pignochino","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lfs.2020.118123_bb0540","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165154","article-title":"In vitro and in vivo antitumor activity of [Pt(O,O\u2019-acac)(gamma-acac)(DMS)] in malignant pleural mesothelioma","volume":"11","author":"Muscella","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.118123_bb0545","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12935-016-0310-9","article-title":"A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2\/M cell cycle transition","volume":"16","author":"Hayashi","year":"2016","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.lfs.2020.118123_bb0550","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3389\/fphar.2018.01269","article-title":"Effect of the BH3 mimetic polyphenol (\u2212)-gossypol (AT-101) on the in vitro and in vivo growth of malignant mesothelioma","volume":"9","author":"Benvenuto","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118123_bb0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181114","article-title":"Apoptosis by [Pt(O,O'-acac)(gamma-acac)(DMS)] requires PKC-delta mediated p53 activation in malignant pleural mesothelioma","volume":"12","author":"Muscella","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.118123_bb0560","doi-asserted-by":"crossref","first-page":"34405","DOI":"10.18632\/oncotarget.14907","article-title":"Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line","volume":"8","author":"Masuelli","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2020.118123_bb0565","doi-asserted-by":"crossref","first-page":"25032","DOI":"10.18632\/oncotarget.15336","article-title":"Activation of JNK and IRE1 is critically involved in tanshinone I-induced p62 dependent autophagy in malignant pleural mesothelioma cells: implication of p62 UBA domain","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2020.118123_bb0570","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.biopha.2016.11.005","article-title":"EGFR-dependent signalling reduced and p38 dependent apoptosis required by gallic acid in malignant mesothelioma cells","volume":"84","author":"Demiroglu-Zergeroglu","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2020.118123_bb0575","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12906-016-1267-x","article-title":"Quercetin and cisplatin combined treatment altered cell cycle and mitogen activated protein kinase expressions in malignant mesotelioma cells","volume":"16","author":"Demiroglu-Zergeroglu","year":"2016","journal-title":"BMC Complement. Altern. Med."},{"key":"10.1016\/j.lfs.2020.118123_bb0580","doi-asserted-by":"crossref","first-page":"416","DOI":"10.14348\/molcells.2015.2268","article-title":"Nrf2 expression and apoptosis in quercetin-treated malignant mesothelioma cells","volume":"38","author":"Lee","year":"2015","journal-title":"Mol Cells"},{"key":"10.1016\/j.lfs.2020.118123_bb0585","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fphar.2017.00373","article-title":"In vitro and in vivo anti-tumoral effects of the flavonoid apigenin in malignant mesothelioma","volume":"8","author":"Masuelli","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118123_bb0590","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.euprot.2016.01.006","article-title":"Comparative proteomic analysis of malignant pleural mesothelioma: focusing on the biphasic subtype","volume":"10","author":"Giusti","year":"2016","journal-title":"EuPA Open Proteom"},{"key":"10.1016\/j.lfs.2020.118123_bb0595","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1268308","article-title":"Prostaglandin E2-mediated adenosinergic effects on CD14(+) cells: self-amplifying immunosuppression in cancer","volume":"6","author":"Al-Taei","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.lfs.2020.118123_bb0600","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.yexcr.2014.12.010","article-title":"Overexpression of activin-A and -B in malignant mesothelioma - attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth","volume":"332","author":"Tamminen","year":"2015","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.lfs.2020.118123_bb0605","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1210\/mend.16.1.0758","article-title":"Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis","volume":"16","author":"Filardo","year":"2002","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.lfs.2020.118123_bb0610","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lfs.2020.118123_bb0615","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cytogfr.2005.01.003","article-title":"Fibroblast growth factor signaling in tumorigenesis","volume":"16","author":"Grose","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.lfs.2020.118123_bb0620","doi-asserted-by":"crossref","first-page":"293","DOI":"10.18632\/oncotarget.22968","article-title":"Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma","volume":"9","author":"Thompson","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2020.118123_bb0625","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.4161\/cc.8.8.8147","article-title":"How ERK1\/2 activation controls cell proliferation and cell death: is subcellular localization the answer?","volume":"8","author":"Mebratu","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.lfs.2020.118123_bb0630","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3389\/fimmu.2017.01559","article-title":"Complement protein C1q binds to hyaluronic acid in the malignant pleural mesothelioma microenvironment and promotes tumor growth","volume":"8","author":"Agostinis","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2020.118123_bb0635","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/carcin\/bgy018","article-title":"FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase\/MMP1 signal","volume":"39","author":"Schelch","year":"2018","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.lfs.2020.118123_bb0640","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3390\/ijms17030322","article-title":"Asbestos induces oxidative stress and activation of Nrf2 signaling in murine macrophages: chemopreventive role of the synthetic lignan secoisolariciresinol diglucoside (LGM2605)","volume":"17","author":"Pietrofesa","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2020.118123_bb0645","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s40495-020-00210-z","article-title":"Emerging insights into anticancer chemopreventive activities of nutraceutical Moringa oleifera: molecular mechanisms, signal transduction and in vivo efficacy","volume":"6","author":"Sodvadiya","year":"2020","journal-title":"Current Pharmacology Reports"},{"key":"10.1016\/j.lfs.2020.118123_bb0650","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40495-019-00195-4","article-title":"Sandalwood oil for the chemoprevention of skin cancer: mechanistic insights, anti-inflammatory, and in vivo anticancer potential","volume":"5","author":"Jain","year":"2019","journal-title":"Current Pharmacology Reports"},{"key":"10.1016\/j.lfs.2020.118123_bb0655","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/aps.2010.147","article-title":"Regulation of Nrf2- and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforaphane in prostate of Nrf2-knockout or C57BL\/6J mice and PC-3 AP-1 human prostate cancer cells","volume":"31","author":"Nair","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.lfs.2020.118123_bb0660","first-page":"12","article-title":"Pharmacometrics of nutraceutical sulforaphane and its implications in prostate cancer prevention","volume":"25","author":"Nair","year":"2016","journal-title":"J. Chin. Pharm. Sci."},{"key":"10.1016\/j.lfs.2020.118123_bb0665","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11095-007-9364-7","article-title":"Synergistic effects of a combination of dietary factors sulforaphane and (\u2212) epigallocatechin-3-gallate in HT-29 AP-1 human colon carcinoma cells","volume":"25","author":"Nair","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.lfs.2020.118123_bb0670","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s13046-019-1368-8","article-title":"Curcumin C3 complex(R)\/Bioperine(R) has antineoplastic activity in mesothelioma: an in vitro and in vivo analysis","volume":"38","author":"Di Meo","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2020.118123_bb0675","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.3892\/mmr.2017.6789","article-title":"Pro-oxidant activity of sulforaphane and cisplatin potentiates apoptosis and simultaneously promotes autophagy in malignant mesothelioma cells","volume":"16","author":"Lee","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.lfs.2020.118123_bb0680","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.canlet.2018.03.032","article-title":"Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation","volume":"425","author":"Chen","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.lfs.2020.118123_bb0685","doi-asserted-by":"crossref","first-page":"478","DOI":"10.5336\/medsci.2012-30329","article-title":"Enhanced cisplatin response with histone acetyl transferase inhibitor, anacardic acid, in malignant pleural mesothelioma cell line","volume":"33","author":"Onen","year":"2013","journal-title":"Turkiye Klinikleri Journal of Medical Sciences"},{"key":"10.1016\/j.lfs.2020.118123_bb0690","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1158\/1535-7163.MCT-05-0293","article-title":"Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin","volume":"5","author":"Shen","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lfs.2020.118123_bb0695","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nrc2129","article-title":"Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer","volume":"7","author":"Liby","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lfs.2020.118123_bb0700","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1208\/s12248-017-0177-2","article-title":"In vitro-in vivo dose response of ursolic acid, sulforaphane, PEITC, and curcumin in cancer prevention","volume":"20","author":"Ramirez","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.lfs.2020.118123_bb0705","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jnutbio.2015.09.014","article-title":"Epigenetic modifications of triterpenoid ursolic acid in activating Nrf2 and blocking cellular transformation of mouse epidermal cells","volume":"33","author":"Kim","year":"2016","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.lfs.2020.118123_bb0710","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymben.2011.02.003","article-title":"Metabolic engineering tanshinone biosynthetic pathway in Salvia miltiorrhiza hairy root cultures","volume":"13","author":"Kai","year":"2011","journal-title":"Metab. Eng."},{"key":"10.1016\/j.lfs.2020.118123_bb0715","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/BF02975249","article-title":"Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death","volume":"23","author":"Chen","year":"2000","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.lfs.2020.118123_bb0720","doi-asserted-by":"crossref","first-page":"9764","DOI":"10.1021\/jf0615707","article-title":"Antioxidant activity of indigenous edible mushrooms","volume":"54","author":"Puttaraju","year":"2006","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.lfs.2020.118123_bb0725","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/10408347.2015.1095064","article-title":"Gallic acid: review of the methods of determination and quantification","volume":"46","author":"Fernandes","year":"2016","journal-title":"Crit. Rev. Anal. Chem."},{"key":"10.1016\/j.lfs.2020.118123_bb0730","first-page":"225","article-title":"Pharmacological effects of gallic acid in health and diseases: a mechanistic review","volume":"22","author":"Kahkeshani","year":"2019","journal-title":"Iran J Basic Med Sci"},{"key":"10.1016\/j.lfs.2020.118123_bb0735","doi-asserted-by":"crossref","DOI":"10.1093\/ecam\/neq053","article-title":"Quercetin and cancer chemoprevention","volume":"2011","author":"Gibellini","year":"2011","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"10.1016\/j.lfs.2020.118123_bb0740","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0887-2333(00)00053-9","article-title":"Flavonoids as peroxynitrite scavengers: the role of the hydroxyl groups","volume":"15","author":"Heijnen","year":"2001","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.lfs.2020.118123_bb0745","doi-asserted-by":"crossref","first-page":"216","DOI":"10.15430\/JCP.2016.21.4.216","article-title":"Role of apigenin in cancer prevention via the induction of apoptosis and autophagy","volume":"21","author":"Sung","year":"2016","journal-title":"J Cancer Prev"},{"key":"10.1016\/j.lfs.2020.118123_bb0750","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1742-7843.2011.00833.x","article-title":"Emerging roles of anacardic acid and its derivatives: a pharmacological overview","volume":"110","author":"Hemshekhar","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.lfs.2020.118123_bb0755","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/j.febslet.2006.06.092","article-title":"Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation","volume":"580","author":"Sun","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.lfs.2020.118123_bb0760","author":"NIH"},{"key":"10.1016\/j.lfs.2020.118123_bb0765","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0770","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0775","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.118123_bb0780","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/s41416-019-0452-3","article-title":"A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours","volume":"120","author":"Mak","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2020.118123_bb0785","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1742-4658.2009.07448.x","article-title":"Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer","volume":"277","author":"Mitsudomi","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.lfs.2020.118123_bb0790","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"issue":"15_suppl","key":"10.1016\/j.lfs.2020.118123_bb0795","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e20030","article-title":"Cetuximab plus platinum-based chemotherapy in patients with malignant pleural mesothelioma: a single arm phase II trial. NCT00996567","volume":"35","author":"De Paepe","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2020.118123_bb0800","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0805","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0810","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0815","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0820","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0825","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0830","author":"ClinicalTrials.gov, NCT03644550"},{"key":"10.1016\/j.lfs.2020.118123_bb0835","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0840","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0845","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0850","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0855","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0860","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0865","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0870","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0875","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0880","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0885","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0890","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0895","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0900","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0905","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0910","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0915","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0920","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0925","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0930","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0935","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0940","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0945","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0950","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0955","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0960","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0965","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0970","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0975","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0980","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0985","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0990","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb0995","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1000","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1005","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1010","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1015","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1020","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1025","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1030","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1035","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1040","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1045","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1050","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1055","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1060","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1065","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1070","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1075","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1080","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1085","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1090","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1095","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1100","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1105","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1110","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1115","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1120","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1125","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1130","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1135","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1140","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1145","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1150","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.lfs.2020.118123_bb1155","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3389\/fonc.2020.00105","article-title":"Manipulating microRNAs for the treatment of malignant pleural mesothelioma: past, present and future","volume":"10","author":"Reid","year":"2020","journal-title":"Front. Oncol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520308742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520308742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T21:11:47Z","timestamp":1765228307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320520308742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":231,"alternative-id":["S0024320520308742"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118123","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New vistas in malignant mesothelioma: MicroRNA architecture and NRF2\/MAPK signal transduction","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"118123"}}